Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,598 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,598 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the completion of the sale, the executive vice president owned 36,606 shares of the company’s stock, valued at $11,993,955.90. This trade represents a 4.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Tolga Tanguler also recently made the following trade(s):

• On Friday, February 13th, Tolga Tanguler sold 1,959 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72.
• On Monday, January 12th, Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $8.65 during trading on Wednesday, reaching $327.30. The company’s stock had a trading volume of 931,139 shares, compared to its average volume of 1,481,848. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company’s fifty day moving average price is $357.29 and its 200-day moving average price is $417.03. The company has a market capitalization of $43.41 billion, a price-to-earnings ratio of 191.40 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the business earned ($0.65) earnings per share. The firm’s quarterly revenue was up 84.9% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on ALNY shares. Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Royal Bank Of Canada dropped their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Finally, Needham & Company LLC dropped their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Thematics Asset Management acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $1,995,000. Mediolanum International Funds Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $11,389,000. Rakuten Investment Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $14,205,000. Generali Asset Management SPA SGR boosted its holdings in shares of Alnylam Pharmaceuticals by 6,368.0% during the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after purchasing an additional 3,184 shares during the last quarter. Finally, Investment Management Corp of Ontario grew its position in shares of Alnylam Pharmaceuticals by 35.4% in the second quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock valued at $10,279,000 after purchasing an additional 8,244 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.